Diabetes risk and provision of diabetes prevention activities in 44 low-income and middle-income countries: a cross-sectional analysis of nationally representative, individual-level survey data.


Journal

The Lancet. Global health
ISSN: 2214-109X
Titre abrégé: Lancet Glob Health
Pays: England
ID NLM: 101613665

Informations de publication

Date de publication:
10 2023
Historique:
received: 04 05 2023
revised: 27 06 2023
accepted: 12 07 2023
medline: 25 9 2023
pubmed: 22 9 2023
entrez: 21 9 2023
Statut: ppublish

Résumé

The global burden of diabetes is rising rapidly, yet there is little evidence on individual-level diabetes prevention activities undertaken by health systems in low-income and middle-income countries (LMICs). Here we describe the population at high risk of developing diabetes, estimate diabetes prevention activities, and explore sociodemographic variation in these activities across LMICs. We performed a pooled, cross-sectional analysis of individual-level data from nationally representative, population-based surveys conducted in 44 LMICs between October, 2009, and May, 2019. Our sample included all participants older than 25 years who did not have diabetes and were not pregnant. We defined the population at high risk of diabetes on the basis of either the presence of impaired fasting glucose (or prediabetes in countries with a haemoglobin A The final pooled sample included 145 739 adults (86 269 [59·2%] of whom were female and 59 468 [40·4%] of whom were male) across 44 LMICs, of whom 59 308 (40·6% [95% CI 38·5-42·8]) were considered at high risk of diabetes (20·6% [19·8-21·5] in low-income countries, 38·0% [37·2-38·9] in lower-middle-income countries, and 57·5% [54·3-60·6] in upper-middle-income countries). Overall, the reach of diabetes prevention activities was low at 40·0% (38·6-41·4) for physical activity counselling, 37·1% (35·9-38·4) for weight loss counselling, 42·7% (41·6-43·7) for dietary counselling, and 37·1% (34·7-39·6) for blood glucose screening. Diabetes prevention varied widely by national-level wealth: 68·1% (64·6-71·4) of people at high risk of diabetes in low-income countries reported none of these activities, whereas 49·0% (47·4-50·7) at high risk in upper-middle-income countries reported at least three activities. Educational attainment was associated with diabetes prevention, with estimated increases in the predicted probability of receipt ranging between 6·5 (3·6-9·4) percentage points for dietary fruit and vegetable counselling and 21·3 (19·5-23·2) percentage points for blood glucose screening, among people with some secondary schooling compared with people with no formal education. A large proportion of individuals across LMICs are at high risk of diabetes but less than half reported receiving fundamental prevention activities overall, with the lowest receipt of these activities among people in low-income countries and with no formal education. These findings offer foundational evidence to inform future global targets for diabetes prevention and to strengthen policies and programmes to prevent continued increases in diabetes worldwide. Harvard T H Chan School of Public Health McLennan Fund: Dean's Challenge Grant Program and the EU's Research and Innovation programme Horizon 2020.

Sections du résumé

BACKGROUND
The global burden of diabetes is rising rapidly, yet there is little evidence on individual-level diabetes prevention activities undertaken by health systems in low-income and middle-income countries (LMICs). Here we describe the population at high risk of developing diabetes, estimate diabetes prevention activities, and explore sociodemographic variation in these activities across LMICs.
METHODS
We performed a pooled, cross-sectional analysis of individual-level data from nationally representative, population-based surveys conducted in 44 LMICs between October, 2009, and May, 2019. Our sample included all participants older than 25 years who did not have diabetes and were not pregnant. We defined the population at high risk of diabetes on the basis of either the presence of impaired fasting glucose (or prediabetes in countries with a haemoglobin A
FINDINGS
The final pooled sample included 145 739 adults (86 269 [59·2%] of whom were female and 59 468 [40·4%] of whom were male) across 44 LMICs, of whom 59 308 (40·6% [95% CI 38·5-42·8]) were considered at high risk of diabetes (20·6% [19·8-21·5] in low-income countries, 38·0% [37·2-38·9] in lower-middle-income countries, and 57·5% [54·3-60·6] in upper-middle-income countries). Overall, the reach of diabetes prevention activities was low at 40·0% (38·6-41·4) for physical activity counselling, 37·1% (35·9-38·4) for weight loss counselling, 42·7% (41·6-43·7) for dietary counselling, and 37·1% (34·7-39·6) for blood glucose screening. Diabetes prevention varied widely by national-level wealth: 68·1% (64·6-71·4) of people at high risk of diabetes in low-income countries reported none of these activities, whereas 49·0% (47·4-50·7) at high risk in upper-middle-income countries reported at least three activities. Educational attainment was associated with diabetes prevention, with estimated increases in the predicted probability of receipt ranging between 6·5 (3·6-9·4) percentage points for dietary fruit and vegetable counselling and 21·3 (19·5-23·2) percentage points for blood glucose screening, among people with some secondary schooling compared with people with no formal education.
INTERPRETATION
A large proportion of individuals across LMICs are at high risk of diabetes but less than half reported receiving fundamental prevention activities overall, with the lowest receipt of these activities among people in low-income countries and with no formal education. These findings offer foundational evidence to inform future global targets for diabetes prevention and to strengthen policies and programmes to prevent continued increases in diabetes worldwide.
FUNDING
Harvard T H Chan School of Public Health McLennan Fund: Dean's Challenge Grant Program and the EU's Research and Innovation programme Horizon 2020.

Identifiants

pubmed: 37734801
pii: S2214-109X(23)00348-0
doi: 10.1016/S2214-109X(23)00348-0
pmc: PMC10560068
mid: NIHMS1932569
pii:
doi:

Substances chimiques

Blood Glucose 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1576-e1586

Subventions

Organisme : World Health Organization
ID : 001
Pays : International
Organisme : NIDDK NIH HHS
ID : K23 DK125162
Pays : United States

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2023 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

JMIR Diabetes. 2019 Apr 15;4(2):e12985
pubmed: 30985289
PLoS Med. 2016 Apr 05;13(4):e1001990
pubmed: 27046234
Lancet. 2021 Jul 17;398(10296):238-248
pubmed: 34274065
Curr Diab Rep. 2016 Sep;16(9):80
pubmed: 27424069
Diabetologia. 2019 Oct;62(10):1842-1853
pubmed: 31451873
Health Aff (Millwood). 2012 Jan;31(1):67-75
pubmed: 22232096
N Engl J Med. 2001 May 3;344(18):1343-50
pubmed: 11333990
Lancet. 2016 Apr 9;387(10027):1513-1530
pubmed: 27061677
Health Aff (Millwood). 2022 Jul;41(7):971-979
pubmed: 35759735
QJM. 2017 May 1;110(5):271-275
pubmed: 27803366
Diabetes Care. 1999 Apr;22(4):623-34
pubmed: 10189543
JAMA Netw Open. 2019 May 3;2(5):e193160
pubmed: 31074808
Health Aff (Millwood). 2017 Mar 1;36(3):564-571
pubmed: 28228484
Diabetes Care. 2023 May 1;46(5):1106
pubmed: 36724041
Lancet. 2004 Jan 10;363(9403):157-63
pubmed: 14726171
Nat Med. 2021 Feb;27(2):193-195
pubmed: 33526928
Diabetes Care. 2020 Apr;43(4):767-775
pubmed: 32051243
Lancet Diabetes Endocrinol. 2019 Mar;7(3):231-240
pubmed: 30704950
Diabetes Care. 2021 Jan;44(1):81-88
pubmed: 33444159
PLoS Med. 2016 Jul 12;13(7):e1002080
pubmed: 27404268
BMJ. 2016 Jan 06;352:h6704
pubmed: 26738745
J Public Health (Oxf). 2018 Jun 1;40(2):350-358
pubmed: 28525612
Lancet Healthy Longev. 2021 Jun;2(6):e340-e351
pubmed: 35211689
Lancet. 2020 Sep 26;396(10255):918-934
pubmed: 32891217
Am J Prev Med. 2019 Mar;56(3):452-457
pubmed: 30661888
PLoS Med. 2018 Jun 6;15(6):e1002575
pubmed: 29874236
JAMA Intern Med. 2017 Dec 1;177(12):1808-1817
pubmed: 29114778
Int J Epidemiol. 2022 Dec 13;51(6):e337-e349
pubmed: 35762972
PLoS Med. 2021 May 25;18(5):e1003574
pubmed: 34032809
Lancet. 2023 Apr 15;401(10384):1302-1312
pubmed: 36931289
Diabetes Care. 2018 May;41(5):963-970
pubmed: 29475843
Diabetes. 1995 May;44(5):483-8
pubmed: 7729603
Sci Rep. 2020 Sep 8;10(1):14790
pubmed: 32901098
Diabetes Care. 2016 Aug;39(8):1364-70
pubmed: 26861922
Health Aff (Millwood). 2013 Jul;32(7):1244-50
pubmed: 23836740
Nutrients. 2019 Oct 01;11(10):
pubmed: 31581478
Nutr Rev. 2004 Jul;62(7 Pt 2):S140-3
pubmed: 15387480
JAMA. 2021 Aug 24;326(8):736-743
pubmed: 34427594
Transl Behav Med. 2020 Feb 3;10(1):46-54
pubmed: 31909412
Diabetes Care. 1997 Apr;20(4):537-44
pubmed: 9096977
Clin Chem. 2005 Sep;51(9):1573-6
pubmed: 16120945
Clin Chim Acta. 2001 May;307(1-2):205-9
pubmed: 11369359
Diabetes Care. 2003 Mar;26(3):725-31
pubmed: 12610029
N Engl J Med. 2002 Feb 7;346(6):393-403
pubmed: 11832527
Diabetes Care. 2018 Jul;41(7):1526-1534
pubmed: 29934481
PLoS Med. 2019 Mar 1;16(3):e1002751
pubmed: 30822339
Lancet. 2012 Nov 17;380(9855):1741-8
pubmed: 23040422

Auteurs

Nicholas Errol Rahim (NE)

Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

David Flood (D)

Department of Medicine, University of Michigan, Ann Arbor, MI, USA.

Maja E Marcus (ME)

Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.

Michaela Theilmann (M)

Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany; Behavioral Science for Disease Prevention and Health Care, Department of Sport and Health Sciences, Technical University of Munich, Munich, Germany.

Taing N Aung (TN)

Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

Kokou Agoudavi (K)

Togo Ministry of Health, Lome, Togo.

Krishna Kumar Aryal (KK)

Bergen Centre for Ethics and Priority Setting, Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.

Silver Bahendeka (S)

Diabetes and Endocrinology, Saint Francis Hospital Nsambya, Kampala, Uganda.

Brice Bicaba (B)

National Institute of Public Health, Ouagadougou, Burkina Faso.

Pascal Bovet (P)

University Center for General Medicine and Public Health (Unisanté), Lausanne, Switzerland; Ministry of Health, Victoria, Seychelles.

Alpha Oumar Diallo (AO)

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.

Farshad Farzadfar (F)

Non-Communicable Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

David Guwatudde (D)

Department of Epidemiology and Biostatistics, School of Public Health, Makerere University, Kampala, Uganda.

Corine Houehanou (C)

Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

Dismand Houinato (D)

Laboratory of Epidemiology of Chronic and Neurological Diseases, Faculty of Health Sciences, University of Abomey-Calavi, Cotonou, Benin.

Nahla Hwalla (N)

Faculty of Agricultural and Food Sciences, American University of Beirut, Beirut, Lebanon.

Jutta Jorgensen (J)

Institute of Global Health, Department of Public Health and Epidemiology, Copenhagen University, Copenhagen, Denmark.

Gibson Bernard Kagaruki (GB)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Mary Mayige (M)

National Institute for Medical Research, Dar es Salaam, Tanzania.

Roy Wong-McClure (R)

Costa Rican Social Security Fund, San José, Costa Rica.

Bagher Larijani (B)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.

Sahar Saeedi Moghaddam (S)

Endocrinology and Metabolism Research Center, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran; Kiel Institute for the World Economy, Kiel, Germany.

Omar Mwalim (O)

Ministry of Health, Zanzibar City, Tanzania.

Kibachio Joseph Mwangi (KJ)

Division of Non-Communicable Diseases, Ministry of Health, Nairobi, Kenya; World Health Organization Country Office, Pretoria, South Africa.

Sudipa Sarkar (S)

Division of Endocrinology, Diabetes, and Metabolism, John Hopkins University, Baltimore, MD, USA.

Abla M Sibai (AM)

Department of Epidemiology and Population Health, Faculty of Health Sciences, American University of Beirut, Beirut, Lebanon.

Lela Sturua (L)

Non-Communicable Disease Department, National Center for Disease Control and Public Health, Tbilisi, Georgia.

Chea Wesseh (C)

Ministry of Health, Monrovia, Liberia.

Pascal Geldsetzer (P)

Division of Primary Care and Population Health, Department of Medicine, Stanford University, Stanford, CA, USA; Chan Zuckerberg Biohub-San Francisco, San Francisco, CA, USA.

Rifat Atun (R)

Department of Global Health and Population, Harvard T H Chan School of Public Health, Harvard University, Boston, MA, USA; Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA.

Sebastian Vollmer (S)

Department of Economics and Centre for Modern Indian Studies, University of Göttingen, Göttingen, Germany.

Till Bärnighausen (T)

Heidelberg Institute of Global Health, Faculty of Medicine and University Hospital, Heidelberg University, Heidelberg, Germany; Department of Global Health and Social Medicine, Harvard Medical School, Harvard University, Boston, MA, USA; Africa Health Research Institute, Somkhele, South Africa.

Justine Davies (J)

MRC/Wits Rural Public Health and Health Transitions Research Unit, School of Public Health, University of Witwatersrand, Johannesburg, South Africa; Institute of Applied Health Research, University of Birmingham, Birmingham, UK; Centre for Global Surgery, Department of Global Health, Stellenbosch University, Cape Town, South Africa.

Mohammed K Ali (MK)

Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, USA; Department of Family and Prevention Medicine, School of Medicine, Emory University, Atlanta, GA, USA.

Jacqueline A Seiglie (JA)

Diabetes Unit, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA.

Jennifer Manne-Goehler (J)

Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. Electronic address: jmanne@partners.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH